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ABSTRACT 
Objective: The objective of this research was to perform a prospective clinical trial to compare antihypertensive effects of amlodipine and 
perindopril in hypertensive patients. 
Methods: In our study, we compared antihypertensive effects of well tolerated and commonly used antihypertensive drugs, amlodipine and 
perindopril. There were 81 hypertensive patients of both sexes over 40 y of age without other diseases included in this prospective clinical trial. 
Forty (40) patients were treated with amlodipine (5 mg/day) and forty-one (41) patients were treated with perindopril (4 mg/day). After one 
month of taking both drugs, blood pressure was measured in the supine position with a standard mercury sphygmomanometer in the morning.  
Results: Amlodipine and perindopril groups were having almost similar characteristics at the beginning of the study. There was significantly decrease 
insystolic blood pressure (sBP) throughout the study period in the amlodipine group (p≤ 0.05) but not in the perindopril group. The efficacy of 
amlodipine over perindopril on systolic blood pressure and diastolic blood pressure (dBP) was significant (p≤ 0.001 for sBP and p≤ 0.05 for dBP). 
Conclusion: It may be concluded that the antihypertensive efficacy of amlodipine was superior when compared to perindopril. 
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Clinically, hypertension is defined as that level of blood pressure 
(BP) at which the institution of therapy reduces blood pressure 
related morbidity and mortality [1]. According to British 
Hypertension Society (BHS) blood pressure is categorized by 
BP<120/80 mmHg is optimal,<130/85 mmHg is normal, 130-
139/85-89 mmHg is high normal, grade-1 hypertension (mild) 
is140-159/90-99 mmHg, grade-2 (moderate) is 160-179/100-109 
mmHg, grade-3 (severe) is systolic ≥180 and diastolic >110 mmHg 
[2]. Antihypertensive drugs are being used tremendously since long 
time ago. In Bangladesh, the prevalence of hypertension was 14.4% 
with systolic blood pressure (sBP) ≥140 mmHg and 9.1% with 
diastolic blood pressure (dBP) ≥ 90 mmHg. Studies from India and 
Bangladesh have shown an upward trend in the prevalence of 
hypertension [3]. For developing countries it is one of the most vital 
problems and if leave untreated leading serious and life threatening 
conditions [4]of the body like heart disease, stroke, end-stage renal 
failure, and peripheral vascular disease. Antihypertensive treatment 
can decrease the rate of cardiovascular morbidity and mortality [5] 
also alleviates the progression of chronic kidney disease [6]. 
In United States, 77% of adults with hypertension used at least one 
antihypertensive medication in large scale of survey [7]. During last 
20 y; several major therapeutic advances have markedly improved 
the prognosis of patients with coronary artery disease (CAD) [3]. 
There are 5 classes of drugs used for the treatment of hypertension 
and prevention of cardiovascular morbidity [5]. Among these drugs, 
two of them; angiotensin converting enzyme (ACE) inhibitors and 
calcium channel blockers (CCB) were used in this study to 
demonstrate their beneficial effects in hypertensive patients [8]. 
Antihypertensive drugs amlodipine and perindopril are widely used 
due to the low incidence of adverse drug reaction and they are well 
tolerated. ACE inhibitors decrease the production of angiotensin II, 
increase bradykinin levels and reduce sympathetic nervous system 
activity [1]. Blockage of bradykinin breakdown and enhancement of 
prostaglandin release may probably participate in the anti-
hypertensive activity of ACE-inhibitors [9]. Perindopril is long acting 
member of ACE inhibitors. This is a prodrug and is converted to the 
active agent by hydrolysis, primarily in the liver [1].  
Calcium channel blockers block voltage-gated calcium channels in 
the heart and vasculature [10]. They reduce vascular resistance, 
which reduces intracellular calcium and blunts vasoconstriction [1] 
due to long lasting relaxation of smooth muscle and a reduction in 
contractility throughout the heart. On heart, it also decreases SA 
node rate and AV nodal conduction velocity [11]. Only about one 
third of all hypertensive patients receiving therapy, however, have 
reached their goal blood pressure (<120/80 mmHg). By controlling 
BP can reduce the risk of developing myocardial infarction, heart 
failure, stroke and renal disease in hypertensive patients [12].  
MATERIALS AND METHODS 
A double-blinded, randomized, parallel-group study was conducted 
in the Department of Pharmacology, Sylhet MAG Osmani Medical 
College, Bangladeshfor 30 d. Eighty-one (81) diagnosed 
hypertensive patients of both sexes of aged between 40 to 80 y were 
taken from the Department of Medicine of Sylhet MAG Osmani 
Medical College Hospital, Bangladesh. 
Permission of research was taken from ethical committee of Sylhet 
Osmani Medical College. Written informed consent was obtained from 
each patient before starting the trial. Among 81 patients 52 were male 
(64.2%) and 29 were female (35.8%). The patients were randomly 
allocated to treatment with either amlodipine 5 mg once a day (n=40) or 
perindopril 4 mg once a day (n=41), for 30 d. Hypertensive patients with 
other co-morbidities like diabetes mellitus (DM), chronic obstructive 
pulmonary disease (COPD), and renal failure (RF) were excluded from 
the study. Then, data were collected by using a pre-diagnosed 
questionnaire. Blood pressure was measured with a standard mercury 
sphygmomanometer in the supine position in the morning and safety 
assessments were made throughout the study period. 
Statistical analysis 
All the data were presented as mean±standard deviation (SD) at 95% 
confidence interval (CI0.95). Statistical analysis was done by applying 
unpaired t-test using Graph pad prism software version 5.0. 
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RESULTS 
Baseline characteristics were almost similar in both study drug groups 
shown in table 1. In amlodipine study group, total subjects were 40 
(male and female ratio was 22/18) whereas, in perindopril study 
group total subjects were 41 (male/female ratio was 30/11). At the 
beginning of the study lying sBP in both amlodipine and perindopril 
groups were 146.13±12.88 mmHg and 149.27±12.97 mmHg 
respectively and lying dBP were 90.50±6.28 mmHg and 89.76±5.36 
mmHg respectively. The sBP and dBPchanges within same study 
groups are depicted in (fig. 1). There was significant decrease of sBP in 
amlodipine treated group after 30 d, but no significant reduction of 
dBP. The sBP and dBP in perindopril treated group were not reduced 
and tentative to increase (fig. 2). The comparative antihypertensive 
efficacy of amlodipine and perindopril (fig. 3). There were significant 
differences of both sBP (amlodipine 141.58±12.52 mmHg, perindopril 
152.93±16.92 mmHg) (p≤ 0.001) and dBP (amlodipine 89.38±7.4 4 
mmHg, perindopril 92.76±7.96 mmHg) (p≤ 0.05) after 30 d. There was 
obviously seen that amlodipine decreasedsBP more effectively (p≤ 
0.001) than dBP. 
 
Table 1: Demographic characteristics of the two studied groups 
Study parameters Amlodipine mean±SD Perindopril mean±SDa a 
Age (Years) 54.10±9.49 55.56±10.09 
Weight (Kg) 64.03±6.39 68.32±4.77 
Lying systolic BP (mm Hg) 146.13±12.88 149.27±12.97 
Lying Diastolic BP (mm Hg) 90.50±6.28 89.76±5.36 
The number of subjects selected for study n= 81 (amlodipine N=40, perindopril N=41). a= mean±Standard deviation (SD) 
 
 
Fig. 1: Comparison of systolic blood pressure (sBP) and 
diastolic blood pressure (dBP) changes in mean±standard 
deviation in amlodipine studied group (N=40) at baseline and 
after 30 d of treatment 
 
 
Fig. 2: Comparison of systolic blood pressure (sBP) and 
diastolic blood pressure (dBP) changes in mean±standard 
deviation in perindopril studied group (N=41) at baseline and 
after 30 d of treatment 
 
 
Fig. 3: Comparison of systolic blood pressure (sBP) and 
diastolic blood pressure (dBP) changes in mean±standard 
deviationbetween amlodipine and perindopril studied group 
(n=81) after 30 d of treatment 
DISCUSSION 
Hypertension is an important worldwide public health challenge 
[13] which is associated with an increased risk of cardiovascular 
mortality, stroke and renal disease. So, controlling of blood pressure 
is essential for the prevention of high BP related morbidity on a 
long-term basis [14-16]. Although lifestyle modification can improve 
for managing hypertension, antihypertensive drug therapy is still 
needed for most hypertensive patients to control BP within normal 
limit [7]. There are many drugs for initial treatment of essential 
hypertension. Considering side effects, drug interactions and co-
morbid conditions, drugs like thiazide diuretics, ACE inhibitors, 
Angiotensin Receptor Blockers (ARBs), CCBs and β-blockers are 
used as first line drugs for the treatment of hypertension. Trials 
compared thiazide diuretics, ACE inhibitors, ARBs and CCBs-did not 
show consistent differences in outcome, efficacy, side effects or 
quality of life. β-blockers which are previously used as a first line 
therapy, have a weaker evidence base. Combination drug therapy 
hasmore advantageous than single drug therapy because of lesser 
side effects. In a study, it was evidenced that perindopril protected 
cardiovascular (CV) events of hypertensive patients in combination 
with other antihypertensive drugs. When perindopril was combined 
with either amlodipine or indapamide, maximal reduction of BP 
resulted indecreased CV deleterious effects [16]. CCB and ACE 
inhibitors might be the suitable combination in treating 
hypertension when ACE inhibitors monotherapy is not sufficient to 
control BP [17]. Though, initially single drug with lower initial doses 
are better tolerated, cost effective and have better compliance. 
In our study, two commonly used drugs were compared on 81 
hypertensive patients. Amlodipine was given to 40 patients, 5 
mg/day and perindopril to 41 patients, 4 mg/day. Amlodipine 
reduced both sBP and dBP from baseline. Amlodipine in compare 
with perindopril significantly reduced sBP (p ≤ 0.001) after one 
month but both drugs were well tolerated. Most frequent adverse 
effect of amlodipine was leg oedema (10.2%) and perindopril was 
coughing (12.5%). The result was comparable with some similar 
studies [18-19]. Zannad, Bernaud and Fay (1999) assessed the 
efficacy of amlodipine and perindopril [18] by Trough: Peak ratio 
from 24h ambulatory BP recordings, before and after active 
treatment period (60 d). Both treatment groups produced 
comparable reduction in clinical sBP and dBP between ‘0’ and ‘60’ 
days. Both sBP and dBP were lowered in amlodipine treated patients 
than perindopril 48 h after last dose. Most frequent adverse effect 
was leg oedema in amlodipine (19.1%) and coughing in perindopril 
(14.3%). After omitting one dose, a condition imitating 
noncompliance, BP was more effectively controlled by amlodipine 
than perindopril. 
Eguchi et al., (2004) compared Valsartan (an ARB) and amlodipine 
(CCB). In that study both drugs significantly reduced sBP and dBP 
(p<0.002) [19]. Antihypertensive effect of amlodipine was superior 
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to valsartan. Morning sBP was significantly reduced by amlodipine 
from 156 to 142 mmHg (p<0.001) but not by valsartan. Both agent 
reduced lowest night sBP to a similar extent (amlodipine 121 to 112 
mmHg, p<0.001; valsartan 123 to 114 mmHg, p<0.002). Reduction 
of morning sBP surge (morning sBP minus lowest night sBP) was 
significantly greater in patients treated with amlodipine compared 
those treated with valsartan (-6.1 mmHg vs+4.5 mmHg. p<0.02). 
Amlodipine monotherapy was more effective than valsartan 
monotherapy in controlling 24 h ambulatory BP and morning BP in 
hypertensive patients. 
CONCLUSION 
In conclusion, our study showed that amlodipine has better efficacy 
than perindopril as initial monotherapy. It was suggested that 
amlodipine is the drug of choice in controlling BP in mild to 
moderate hypertension when compared with perindopril. Further 
studies are required comparing other antihypertensive drugs and 
with incresed sample size to identify the risks and benefits of 
amlodipine to prove its efficacy compared to other antihypertensive 
drugs as monotherapy in mild to moderate hypertension. 
Study limitation 
In our study the number of patients was limited (81) and the study 
duration was only one month. 
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